does tirzepatide cause rapid heart rate is a next-generation dual agonist that targets both GLP-1 and GIP receptors to help regulate appetite, support metabolic balance, and drive meaningful weight loss. To match your unique physiology and treatment Tirzepatide for Heart Failure in

Key Takeaway: Nausea is most common during the startup phase of treatment

It also adds uncertainty without proving better long-term outcomes

Understanding these side effects is vital for weight loss seekers to make informed decisions about their treatment options

placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes